Reported about 1 year ago
With the opening of the Asia Biotech Expo in July, Poya and Shiyang are benefiting. Poya expects a 15%-20% growth in CDMO revenue this year with over 15 commercialized production projects globally, while Shiyang plans to expand its production capacity for colored contact lenses from 5 million to 10 million per month by year-end. Poya recently acquired a sterile drug manufacturing plant in Maryland, USA, aiming to enhance its CDMO capacity. Shiyang's revenue is expected to surpass last year's full-year earnings by the end of the first half of this year, showing strong growth potential.
Source: YAHOO